U-46619 is a TP receptor agonist that exhibits properties similar to Thromboxane A2, inducing platelet aggregation and vascular smooth muscle contraction. 5-trans U-46619 is a minor impurity (2-5%) which is variably present in most commercial preparations of U-46619. The biological activity of 5-trans U-46619 has rarely been tested separately from U-46619 itself. In the only case published to date, 5-trans U-46619 was found to be a about half as potent an inhibitor of Prostaglandin E synthase as the 5-cis version of U-46619.[Cayman Chemical]
5-trans u-46619 is a minor impurity (2-5%) which variably exists in most commercial preparations of u-46619 [1]. u-46619 is a selective thromboxane a2 agonist involved in inducing platelet aggregation and vascular smooth muscle contraction [2].the biological activity of 5-trans u-46619 has been rarely tested separately from u-46619 itself. in the only case published to date, 5-trans u-46619 was found to be a about half as potent an inhibitor of prostaglandin e synthase as the 5-cis version of u-46619 [1]. thromboxane a2 (txa2) has been involved in the pathogenesis of airway hyperresponsiveness. txa2 is a type of thromboxane produced by activated platelets and shows prothrombotic properties. thromboxane a2 has also been known as a vasoconstrictor and is especially important during tissue injury and inflammation [3].
[1] quraishi o, mancini j a, riendeau d. inhibition of inducible prostaglandin e 2 synthase by 15-deoxy-δ 12, 14-prostaglandin j 2 and polyunsaturated fatty acids[j]. biochemical pharmacology, 2002, 63(6): 1183-1189.
[2] coleman, r. a.,humphrey, p.p.a.,kennedy, i., et al. comparison of the actions of u-46619, a prostaglandin h2-analogue, with those of prostaglandin h2 and thromboxane a2 on some isolated smooth muscle preparations. british journal of pharmacology 73, 773-778 (1981).
[3] svensson j, strandberg k, tuvemo t, et al. thromboxane a2: effects of airway and vascular smooth muscle[j]. prostaglandins, 1977, 14(3): 425-436.
